contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


karolinska-developments-portfolio-company-biosergen-publishes-prospectus-due-to-rights-issue-of-units

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Karolinska Development is a Nordic investment company in the life science sector. The company focuses on identifying medical innovations to create and develop companies that further develop such innovations into differentiated products. Karolinska Development's portfolio consists of a number of companies focused on developing treatment methods for diseases that are classified as life-threatening and serious. The largest business operations are in the Nordic market.

Karolinska Development

STOCKHOLM, Sweden, March 14 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen has published a prospectus for the issue of units that was...

STOCKHOLM, Sweden, March 14 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen has published a prospectus for the issue of units that was approved during a extraordinary general meeting on March 1, 2024. The prospectus has been approved by the Swedish Financial Supervisory Authority and contains complete terms and conditions for the issue of units of shares and warrants with preferential rights for existing shareholders. The prospectus is now available on the company <a href="https://www.globenewswire.com/Tracker?data=njD0FI4WScLTwR0ufYHZ1EzrnztvtBXInXJwZZXoGrDCgjSo-CLASv9yR3zPhaqhTawCd2pBoy9NHPKhk_BnvxF5dEigGUv4ElhqBcOaNkiPog1LM7BHJTtSm4ISQVO8">website</a>. The subscription period will run from March 7, 2024, up to, and including, March 21, 2024. Karolinska Development's shareholding in Biosergen, through ownership by KDev Investments, amounts to 2 percent. For further information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: <a href="https://www.globenewswire.com/Tracker?data=7XTdPhqYjnZlIZHIXxB8GWi8n2Eyx6zRxL3-mCiYLYmesS-p0lUxnL6vOUo0QnLgK_Rw5UoH0rIwClCGV9GCbzWJFCrtczaC-CM92refdbQWs1i5Bz5SFvygGEPCwSlXV9ANSIYCn_LEpeBWb_Ex3g==">viktor.drvota@karolinskadevelopment.com</a>&nbsp; Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB Phone: +46&nbsp;70&nbsp;207 48 26, e-mail: <a href="https://www.globenewswire.com/Tracker?data=-lvBXDXUgoUGAXvTdxvSPPDWYcaor1Qe5Sc2D7_r_MDo3XrrNxhmVoPVNJpdKX5rY0iyapFZsqCyLbw3jnbv0VUL3RM4T79eeZaAtH6f3hJusHJyqYLcvZOGjFQrPEuqJ71akea8it0rugecUaZ-FQ==">johan.dighed@karolinskadevelopment.com</a> TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patient’s lives while providing an attractive return on investment to shareholders. Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success. Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases. The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=dBodhepCvI6iC8H3gBEjCfUODc2Enf31QUYwMmql0vmI5527-j_tBI3G8zbP9K1s9rsQUG7-IiO5DFu3lwkKZu7MpPkBTaT2w5SBA8hZPyfklI5u0q8ILOTbNd4xNeOt">www.karolinskadevelopment.com</a>. Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/5c80afe2-7285-4cf3-83f2-095a8a168039">KD Biosergen -Rights issue- eng</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMDkyOTE2MiM0MDE3ODMyMjkjMjAwMDcyNQ=="> <img src="https://ml-eu.globenewswire.com/media/ZGMxMGI5MjktYTEyMC00YWQ0LWIyNGItNjI2M2YyNTAyYWNmLTEwMTIyOTg=/tiny/Karolinska-Development-AB-publ.png">

Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Drug development investment: Value creation through M&As and licensing agreements

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Stay up to date with our newsletter